Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.63 -4.4%	$2.09	$1.03 ▼ $2.99	$550.93M	1.44	2.05 million shs	4.34 million shs
DNA Ginkgo Bioworks	$11.17 -1.6%	$8.49	$5.00 ▼ $16.85	$664.34M	1.48	1.43 million shs	1.17 million shs
NKTX Nkarta	$1.78 +5.3%	$1.83	$1.31 ▼ $8.23	$119.92M	0.7	1.03 million shs	370,412 shs
ZVRA Zevra Therapeutics	$11.55 +2.5%	$8.79	$4.48 ▼ $11.59	$616.24M	1.97	708,929 shs	1.44 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	-4.36%	-2.95%	+9.13%	+102.31%	+107.09%
DNA Ginkgo Bioworks	-1.85%	-1.76%	+47.56%	+64.02%	-16.47%
NKTX Nkarta	+5.33%	+4.09%	-6.32%	+13.38%	-66.42%
ZVRA Zevra Therapeutics	+2.48%	+29.05%	+24.73%	+68.61%	+157.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.0168 of 5 stars	3.8	3.0	2.4	1.7	0.6
DNA Ginkgo Bioworks	1.2412 of 5 stars	1.0	2.0	3.4	2.5	1.3
NKTX Nkarta	2.0644 of 5 stars	3.6	1.0	1.9	1.7	0.6
ZVRA Zevra Therapeutics	2.7607 of 5 stars	3.6	3.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.50	Strong Buy	$9.00	242.21% Upside
DNA Ginkgo Bioworks	2.00	Hold	$8.50	-23.90% Downside
NKTX Nkarta	3.13	Buy	$14.33	705.24% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.14	100.37% Upside

Current Analyst Ratings Breakdown

Latest NKTX, DNA, ATAI, and ZVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,699.66	N/A	N/A	$0.69 per share	3.81
DNA Ginkgo Bioworks	$227.04M	2.88	N/A	N/A	$13.17 per share	0.85
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
ZVRA Zevra Therapeutics	$23.61M	26.75	N/A	N/A	$0.74 per share	15.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$9.16	N/A	N/A	N/A	-198.84%	-52.35%	-27.14%	8/14/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	57.75	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest NKTX, DNA, ATAI, and ZVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
DNA Ginkgo Bioworks	N/A	4.88	4.88
NKTX Nkarta	N/A	14.48	14.48
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
DNA Ginkgo Bioworks	78.63%
NKTX Nkarta	80.54%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
DNA Ginkgo Bioworks	9.72%
NKTX Nkarta	8.40%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

NKTX, DNA, ATAI, and ZVRA Headlines

Recent News About These Companies

Noteworthy Monday Option Activity: ZVRA, U, WNS | Nasdaq

July 8 at 6:33 PM | nasdaq.com

Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading Volume - What's Next?

July 7 at 12:23 PM | marketbeat.com

Equities Analysts Issue Forecasts for ZVRA Q2 Earnings

July 6 at 2:33 AM | americanbankingnews.com

Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? - Nasdaq

July 5, 2025 | nasdaq.com

What is HC Wainwright's Forecast for ZVRA Q2 Earnings?

July 4, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Hits New 12-Month High - Still a Buy?

July 4, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 5.9% - Still a Buy?

July 3, 2025 | marketbeat.com

Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?

July 3, 2025 | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at HC Wainwright

July 2, 2025 | marketbeat.com

Carret Asset Management LLC Buys Shares of 36,140 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 21, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts

June 20, 2025 | marketbeat.com

Cantor Fitzgerald Predicts ZVRA FY2026 Earnings

June 11, 2025 | marketbeat.com

Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 9, 2025 | marketbeat.com

Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 31, 2025 | finanznachrichten.de

Zevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth Strategy

May 31, 2025 | nasdaq.com

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025 | globenewswire.com

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27, 2025 | insidermonkey.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 13, 2025 | taiwannews.com.twT

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, DNA, ATAI, and ZVRA Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.63 -0.12 (-4.36%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$2.70 +0.06 (+2.47%)

As of 04:02 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Ginkgo Bioworks NYSE:DNA

$11.17 -0.18 (-1.59%)

Closing price 07/8/2025 03:59 PM Eastern

Extended Trading

$11.16 -0.01 (-0.09%)

As of 04:09 AM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Nkarta NASDAQ:NKTX

$1.78 +0.09 (+5.33%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$1.78 -0.01 (-0.28%)

As of 07/8/2025 07:56 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Zevra Therapeutics NASDAQ:ZVRA

$11.55 +0.28 (+2.48%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$11.47 -0.08 (-0.68%)

As of 07/8/2025 07:56 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time